Tesamorelinsafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for Tesamorelin as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. Tesamorelin is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Tesamorelin has the most extensive published clinical-trial safety dataset of any GH-axis peptide, accumulated through the pivotal Phase III HIV-lipodystrophy programme (multiple trials with combined enrolment >1,000 patients) and post-marketing surveillance since the 2010 FDA approval. The principal documented adverse events include injection-site reactions (erythema, pruritus, transient nodules — frequent but mild), arthralgia and peripheral oedema (~15-25%), paraesthesias (~10-15%), and the metabolic effects expected of GH-axis activation — modest insulin resistance with elevated fasting glucose and HbA1c in susceptible individuals. Fluid retention with peripheral oedema is the most consistent symptomatic adverse event of GH-axis activation, mediated by GH-driven renal sodium and water retention. In the tesamorelin Phase III programme, peripheral oedema was the most common adverse event leading to discontinuation, particularly in patients with pre-existing cardiac or renal disease. Joint pain (arthralgia), particularly in the small joints of the hands, reflects similar fluid-retention and connective-tissue effects of GH activation and is dose- and duration-dependent. The insulin resistance signal from tesamorelin is materially smaller than chronic recombinant somatropin given the preservation of the IGF-1 negative-feedback loop, but is non-zero. Fasting glucose and HbA1c rose modestly in the Phase III treated arms compared to placebo, and pre-existing diabetes is a recognised exacerbating factor. The FDA label requires glucose monitoring during chronic tesamorelin therapy. The theoretical oncology concerns common to GH-axis activation — sustained IGF-1 elevation theoretically increasing IGF-1R-driven tumour growth — were addressed in the Phase III programme with cancer-related exclusion criteria. Post-marketing surveillance has not identified a clear cancer signal, though the dataset duration is limited to ~15 years since approval. Active malignancy and recent cancer history remain FDA-label contraindications. Anti-tesamorelin antibodies develop in approximately 50% of chronically treated patients but are generally not neutralising and have not been associated with documented loss of efficacy or with hypersensitivity reactions. Acute hypersensitivity reactions including rare reports of acute pancreatitis exist in post-marketing data and are reflected in the FDA label. Serious adverse events specifically attributable to tesamorelin (excluding events related to the underlying HIV disease) have been uncommon. The overall safety record is the strongest of the GH-axis peptide class and reflects the relatively conservative IGF-1 elevation produced by tesamorelin's pulsatile-preserving mechanism.

UK regulatory status

Tesamorelin is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no UK marketing authorisation. The Theratechnologies EMA marketing authorisation application was withdrawn in 2014, so the compound has no European Union licensing position to inherit. It is not a controlled substance under the Misuse of Drugs Act 1971. Tesamorelin holds current FDA approval (Egrifta and Egrifta SV) for HIV-associated lipodystrophy in the United States. This FDA approval does not confer UK marketing authorisation. Specialist access for individual UK patients with HIV-associated lipodystrophy through the unlicensed-medicines framework (Regulation 167 of the Human Medicines Regulations 2012, the 'specials' route) is theoretically possible via a named prescriber and an importation arrangement, but is rarely pursued in practice given the limited UK lipodystrophy population and the cost of imported specialist medicines. Tesamorelin is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone-releasing hormone analogue. Athletes subject to anti-doping testing should treat tesamorelin as prohibited both in-competition and out-of-competition regardless of claimed research or therapeutic purpose. Research-grade tesamorelin for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply for human use outside an authorised clinical-trial framework or specials importation engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA, tesamorelin requires standard project and personal licences.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. Tesamorelin is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full Tesamorelin research context including mechanism, study citations, and references, see the main Tesamorelin research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.